CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · see citing works

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377 · see citing works

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · see citing works

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157 · see citing works

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · see citing works

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · see citing works

Pembrolizumab versus Ipilimumab in Advanced Melanoma

Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · see citing works

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807 · see citing works

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation

Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · see citing works

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101 · see citing works

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

Postow, M. A., Sidlow, R., & Hellmann, M. D. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1703481 · Cited by 4,849 · see citing works

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,684 · see citing works

Nivolumab plus Ipilimumab in Advanced Melanoma

Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · see citing works

Enhancement of Antitumor Immunity by CTLA-4 Blockade

Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955 · see citing works

Cancer immunotherapy comes of age

Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893 · see citing works

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · see citing works

PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma

Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A. S., Scott, E. C., Gutierrez, M. E., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,564 · see citing works

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395 · see citing works

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,373 · see citing works

Nivolumab in Patients with Metastatic DNA Mismatch Repair-Deficient or Microsatellite Instability-High Colorectal Cancer (CheckMate 142): An Open-Label, Multicentre, Phase 2 Study

Overman, M. J., McDermott, R., Leach, J. L., Lonardi, S., Lenz, H.-J., Morse, M. A., Desai, J., Hill, A., Axelson, M., Moss, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30422-9 · Cited by 2,836 · see citing works

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781 · see citing works

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756 · see citing works

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Weber, J. S., D’Angelo, S. P., Minor, D. R., Hodi, F. S., Gutzmer, R., Neyns, B., Höeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676 · see citing works

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab

Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222 · see citing works

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199 · see citing works

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774 · see citing works

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

Sharma, P., Retz, M. M., Siefker-Radtke, A. O., Baron, A. D., Necchi, A., Bedke, J., Plimack, E. R., Vaena, D. A., Grimm, M., Sergio Bracarda, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30065-7 · Cited by 1,729 · see citing works

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

Ribas, A., Puzanov, I. J., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,580 · see citing works

Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial

Kwon, E. D., Drake, C. G., Scher, H. I., Fizazi, K., Bossi, A., van den Eertwegh, A. J. M., Krainer, M., Houede, N., Santos, R., Mahammedi, H., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70189-5 · Cited by 1,511 · see citing works

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Rizvi, N. A., Mazières, J., Planchard, D., Stinchcombe, T. E., Dy, G. K., Antonia, S. J., Horn, L., Lena, H., Minenza, E., Mennecier, B., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70054-9 · Cited by 1,415 · see citing works

Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab

Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415 · see citing works

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study

Langer, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30498-3 · Cited by 1,404 · see citing works

Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma

Parsa, A. T., Waldron, J. S., Panner, A., Crane, C. A., Parney, I. F., Barry, J. J., Cachola, K. E., Murray, J. C., Tihan, T., Jensen, M. C., et al. (2006) · Nature Medicine · doi:10.1038/nm1517 · Cited by 1,341 · see citing works

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

Eggermont, A. M. M., Chiarion‐Sileni, V., Grob, J., Dummer, R., Wolchok, J. D., Schmidt, H., Hamid, O., Robert, C., Ascierto, P. A., Richards, J. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611299 · Cited by 1,319 · see citing works

PD-1 Blockade with pembrolizumab in advanced Merkel-cell carcinoma

Nghiem, P. T., Bhatia, S., Lipson, E. J., Kudchadkar, R. R., Miller, N. J., Annamalai, L., Berry, S., Chartash, E. K., Daud, A., Fling, S. P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603702 · Cited by 1,258 · see citing works

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244 · see citing works

Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial

Kaufman, H. L., Russell, J., Hamid, O., Bhatia, S., Terheyden, P., D'Angelo, S. P., Shih, K. C., Lebbé, C., Linette, G. P., Milella, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30364-3 · Cited by 1,236 · see citing works

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

Wolchok, J. D., Neyns, B., Linette, G., Negrier, S., Lutzky, J., Thomas, L., Waterfield, W., Schadendorf, D., Smylie, M., Guthrie, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70334-1 · Cited by 1,195 · see citing works

Cancer immunotherapy: the beginning of the end of cancer?

Farkona, S., Diamandis, E. P., & Blasutig, I. M. (2016) · BMC Medicine · doi:10.1186/s12916-016-0623-5 · Cited by 1,192 · see citing works

Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

Gettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., Powderly, J. D., Heist, R. S., Carvajal, R. D., Jackman, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3708 · Cited by 1,180 · see citing works

Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial

Muro, K., Chung, H. C., Shankaran, V., Geva, R., Catenacci, D. V. T., Gupta, S., Eder, J. P., Golan, T., Le, D. T., Burtness, B. A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)00175-3 · Cited by 1,117 · see citing works

Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial

Margolin, K., Ernstoff, M. S., Hamid, O., Lawrence, D., McDermott, D., Puzanov, I., Wolchok, J. D., Clark, J. I., Sznol, M., Logan, T. F., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70090-6 · Cited by 1,091 · see citing works

Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma

Ribas, A., Hamid, O., Daud, A., Hodi, F. S., Wolchok, J. D., Kefford, R., Joshua, A. M., Patnaik, A., Hwu, W.-J., Weber, J. S., et al. (2016) · JAMA · doi:10.1001/jama.2016.4059 · Cited by 1,069 · see citing works

Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center

Horvat, T. Z., Adel, N. G., Dang, T.-O., Momtaz, P., Postow, M. A., Callahan, M. K., Carvajal, R. D., Dickson, M. A., D'Angelo, S. P., Woo, K. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8448 · Cited by 1,064 · see citing works

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

Chen, R., Zinzani, P. L., Fanale, M. A., Armand, P. A., Johnson, N. A., Brice, P., Radford, J. A., Ribrag, V., Molin, D. L., Vassilakopoulos, T. P., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1316 · Cited by 991 · see citing works

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

Younes, A., Santoro, A., Shipp, M. A., Zinzani, P. L., Timmerman, J. M., Ansell, S. M., Armand, P. A., Fanale, M. A., Ratanatharathorn, V., Kuruvilla, J. G., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30167-x · Cited by 928 · see citing works

Safety and efficacy of durvalumab (MEDI4736), an anti–programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer

Massard, C., Gordon, M. S., Sharma, S., Rafii, S., Wainberg, Z. A., Luke, J., Curiel, T. J., Colon-Otero, G., Hamid, O., Sanborn, R. E., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9761 · Cited by 840 · see citing works

Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma

Gao, Q., Wang, X., Qiu, S., Yamato, I., Sho, M., Nakajima, Y., Zhou, J., Li, B., Shi, Y., Xiao, Y., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1608 · Cited by 810 · see citing works

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

Hodi, F. S., Hwu, W., Kefford, R. F., Weber, J. S., DAUD, A. I., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Gangadhar, T. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0391 · Cited by 735 · see citing works

Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

Bertrand, A., Kostine, M., Barnetche, T., Truchetet, M.-E., & Schaeverbeke, T. (2015) · BMC Medicine · doi:10.1186/s12916-015-0455-8 · Cited by 704 · see citing works

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

Bauml, J. M., Seiwert, T. Y., Pfister, D. G., Worden, F. P., Liu, S. V., Gilbert, J., Saba, N. F., Weiss, J., Wirth, L. J., Sukari, A. W., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1524 · Cited by 662 · see citing works

Metastasis of Uveal Melanoma Millimeter-by-Millimeter in 8033 Consecutive Eyes

Shields, C. L. (2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.208 · Cited by 633 · see citing works

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study

Antonia, S., Goldberg, S. B., Balmanoukian, A., Chaft, J. E., Sanborn, R. E., Gupta, A., Narwal, R., Steele, K., Gu, Y., Karakunnel, J. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00544-6 · Cited by 602 · see citing works

Bevacizumab plus ipilimumab in patients with metastatic melanoma

Hodi, F. S., Lawrence, D., Lezcano, C., Wu, X., Zhou, J., Sasada, T., Zeng, W., Giobbie-Hurder, A., Atkins, M. B., Ibrahim, N., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0053 · Cited by 593 · see citing works

Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study

Apolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., Mega, A. E., Britten, C. D., Ravaud, A., Mita, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6795 · Cited by 585 · see citing works

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy

Zimmer, L., Goldinger, S. M., Hofmann, L., Loquai, C., Ugurel, S., Thomas, I., Schmidgen, M. I., Gutzmer, R., Utikal, J. S., Göppner, D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.024 · Cited by 564 · see citing works

CTLA-4 Blockade with Ipilimumab: Long-term Follow-up of 177 Patients with Metastatic Melanoma

Prieto, P. A., Yang, J. C., Sherry, R. M., Hughes, M. S., Kammula, U. S., White, D. E., Levy, C. L., Rosenberg, S. A., & Phan, G. Q. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1823 · Cited by 477 · see citing works

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

Voskens, C., Goldinger, S. M., Loquai, C., Robert, C., Kaehler, K. C., Berking, C., Bergmann, T., Bockmeyer, C. L., Eigentler, T., Fluck, M., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053745 · Cited by 463 · see citing works

Rheumatic and Musculoskeletal Immune‐Related Adverse Events Due to Immune Checkpoint Inhibitors: A Systematic Review of the Literature

Cappelli, L. C., Gutierrez, A. K., Bingham, C. O., & Shah, A. A. (2016) · Arthritis Care & Research · doi:10.1002/acr.23177 · Cited by 404 · see citing works

Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab

Cappelli, L. C., Gutierrez, A. K., Baer, A. N., Albayda, J., Manno, R., Haque, U. J., Lipson, E. J., Bleich, K. B., Shah, A. A., Naidoo, J., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209595 · Cited by 397 · see citing works

CLINICAL SPECTRUM AND PROGNOSIS OF UVEAL MELANOMA BASED ON AGE AT PRESENTATION IN 8,033 CASES

Shields, C. L., Kaliki, S., Furuta, M., et al. (2012) · Retina · doi:10.1097/iae.0b013e31824d09a8 · Cited by 326 · see citing works

Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma

Liao, B., Shroff, S., Kamiya-Matsuoka, C., & Tummala, S. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou001 · Cited by 288 · see citing works

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

Zimmer, L., Vaübel, J., Mohr, P., Hauschild, A., Utikal, J. S., Simon, J. C., Garbe, C., Herbst, R. A., Enk, A., Kämpgen, E., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118564 · Cited by 268 · see citing works

Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors

Makarious, D., Horwood, K., & Coward, J. I. G. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.041 · Cited by 263 · see citing works

Ocular immune privilege

Zhou, R., & Caspi, R. R. (2010) · F1000 Biology Reports · doi:10.3410/b2-3 · Cited by 259 · see citing works

Safety, Correlative Markers, and Clinical Results of Adjuvant Nivolumab in Combination with Vaccine in Resected High-Risk Metastatic Melanoma

Gibney, G. T., Kudchadkar, R. R., DeConti, R. C., Thebeau, M. S., Czupryn, M. P., Tetteh, L. F., Eysmans, C. E., Richards, A. D., Schell, M. J., Fisher, K. J., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2468 · Cited by 257 · see citing works

The Mechanism of Anti-CTLA-4 Activity and the Negative Regulation of T-Cell Activation

Wolchok, J. D., & Saenger, Y. M. (2008) · The Oncologist · doi:10.1634/theoncologist.13-s4-2 · Cited by 250 · see citing works

Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab

Weber, J., Gibney, G., Kudchadkar, R., Yu, B., Cheng, P., Martinez, A. J., Kroeger, J., Richards, A., McCormick, L., Moberg, V., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0193 · Cited by 248 · see citing works

Conjunctival Melanomas Harbor BRAF and NRAS Mutations and Copy Number Changes Similar to Cutaneous and Mucosal Melanomas

Griewank, K., Westekemper, H., Murali, R., Mach, M., Schilling, B., Wiesner, T., Schimming, T. T., Livingstone, E., Sucker, A., Grabellus, F., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0163 · Cited by 227 · see citing works

Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition

Heppt, M. V., Heinzerling, L., Kähler, K. C., Forschner, A., Kirchberger, M. C., Loquai, C., Meißner, M., Meier, F. E., Terheyden, P. A. M., Schell, B., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.038 · Cited by 199 · see citing works

Management of conjunctival malignant melanoma: a review and update

Wong, J. R., Nanji, A., Galor, A., & Karp, C. L. (2014) · Expert Review of Ophthalmology · doi:10.1586/17469899.2014.921119 · Cited by 198 · see citing works

Myasthenic crisis and polymyositis induced by one dose of nivolumab

Kimura, T., Fukushima, S., Miyashita, A., Aoi, J., Jinnin, M., Kosaka, T., Ando, Y., Matsukawa, M., Inoue, H., Kiyotani, K., et al. (2016) · Cancer Science · doi:10.1111/cas.12961 · Cited by 192 · see citing works

Drug‐Associated Polymyalgia Rheumatica/Giant Cell Arteritis Occurring in Two Patients After Treatment With Ipilimumab, an Antagonist of CTLA‐4

Goldstein, B. L., Gedmintas, L., & Todd, D. J. (2013) · Arthritis & Rheumatology · doi:10.1002/art.38282 · Cited by 185 · see citing works

Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy

Min, L., Vaidya, A., & Becker, C. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0833 · Cited by 179 · see citing works

Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review

Abdel-Rahman, O. M., Oweira, H., Petrausch, U., Helbling, D., Schmidt, J., Mannhart, M., Mehrabi, A., Schöb, O. M., & Giryes, A. (2017) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1296765 · Cited by 163 · see citing works

Cytotoxic T Lymphocyte-Associated Antigen 4 Blockade in Patients with Metastatic Melanoma

Robinson, M. R., Chan, C. C., Yang, J. C.-H., Rubin, B. I., Gracia, G. J., Sen, H. N., Csaky, K. G., & Rosenberg, S. A. (2004) · Journal of Immunotherapy · doi:10.1097/00002371-200411000-00008 · Cited by 159 · see citing works

Autoimmune Retinopathy

Grange, L. K., Dalal, M. D., Nussenblatt, R. B., & Sen, H. N. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.09.019 · Cited by 155 · see citing works

Acetylcholine receptor binding antibody-associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma

Shirai, T., Sano, T., Kamijo, F., Saito, N., Miyake, T., Kodaira, M., Katoh, N., Nishie, K., Okuyama, R., & Uhara, H. (2015) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyv158 · Cited by 137 · see citing works

Ocular and orbital side-effects of checkpoint inhibitors: a review article

Antoun, J. S., Titah, C., & Cochereau, I. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000296 · Cited by 137 · see citing works

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy

Danielli, R., Ridolfi, R., Chiarion‐Sileni, V., Queirolo, P., Testori, A., Plummer, R., Boitano, M., Calabrò, L., Rossi, C. D., Giacomo, A. M. D., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1089-0 · Cited by 136 · see citing works

Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.

Wolchok, J. D., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Schadendorf, D., de Pril, V., Heller, K. N., Chen, T., Ibrahim, R. A., et al. (2010) · PubMed Central · Cited by 133 · see citing works

Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events

Davies, M. J., & Duffield, E. (2017) · ImmunoTargets and Therapy · doi:10.2147/itt.s141577 · Cited by 129 · see citing works

Ipilimumab-induced Ocular and Orbital Inflammation—A Case Series and Review of the Literature

Papavasileiou, E., Prasad, S., Freitag, S. K., Sobrin, L., & Lobo, A. (2015) · Ocular Immunology and Inflammation · doi:10.3109/09273948.2014.1001858 · Cited by 128 · see citing works

Drug-Induced Graves Disease From CTLA-4 Receptor Suppression

Borodic, G., Hinkle, D. M., & Cia, Y. (2011) · Ophthalmic Plastic &amp; Reconstructive Surgery · doi:10.1097/iop.0b013e3181ef72a1 · Cited by 120 · see citing works

Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma

Johnson, D. B., Saranga‐Perry, V., Lavin, P., Burnette, W. B., Clark, S. W., Uskavitch, D., Wallace, D. E., Dickson, M. A., Kudchadkar, R. R., & Sosman, J. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.1683 · Cited by 111 · see citing works

The use of pembrolizumab for the treatment of metastatic uveal melanoma

Kottschade, L. A., McWilliams, R. R., Markovic, S. N., Block, M. S., Villasboas, J. C., Pham, A., Esplin, B. L., & Dronca, R. S. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000242 · Cited by 110 · see citing works

A phase 2 study of tremelimumab in patients with advanced uveal melanoma

Joshua, A. M., Monzon, J. G., Mihalcioiu, C. L. D., Hogg, D., Smylie, M., & Cheng, T. (2015) · Melanoma Research · doi:10.1097/cmr.0000000000000175 · Cited by 105 · see citing works

Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review

Heppt, M. V., Steeb, T., Schlager, J. G., Rosumeck, S., Dressler, C., Ruzicka, T., Nast, A., & Berking, C. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.08.009 · Cited by 104 · see citing works

Myasthenia triggered by immune checkpoint inhibitors: New case and literature review

Gonzalez, N. L., Puwanant, A., Lu, A., Marks, S. M., & Živković, S. (2017) · Neuromuscular Disorders · doi:10.1016/j.nmd.2017.01.002 · Cited by 103 · see citing works

Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer

Loochtan, A. I., Nickolich, M. S., & Hobson‐Webb, L. D. (2015) · Muscle & Nerve · doi:10.1002/mus.24648 · Cited by 101 · see citing works

Personalized Prognosis of Uveal Melanoma Based on Cytogenetic Profile in 1059 Patients over an 8-Year Period

Shields, C. L., Say, E. A. T., Hasanreisoğlu, M., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.04.003 · Cited by 97 · see citing works

Thyroid-Like Ophthalmopathy in a Euthyroid Patient Receiving Ipilimumab

McElnea, E., Ní Mhéalóid, Á., Moran, S., Kelly, R., & Fulcher, T. (2014) · Orbit · doi:10.3109/01676830.2014.949792 · Cited by 93 · see citing works

Vogt-Koyanagi-Harada-like Syndrome After CTLA-4 Inhibition With Ipilimumab for Metastatic Melanoma

Crosson, J. N., Laird, P. W., Debiec, M. R., Bergstrom, C. S., Lawson, D. H., & Yeh, S. (2015) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000066 · Cited by 91 · see citing works

Clinical activity and safety of Pembrolizumab in Ipilimumab pre-treated patients with uveal melanoma

Karydis, I., Chan, P. Y., Wheater, M. J., Arriola, E., Szlosarek, P. W., & Ottensmeier, C. H. H. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1143997 · Cited by 91 · see citing works

Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma

Manusow, J. S., Khoja, L., Pesin, N., et al. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0041-1 · Cited by 90 · see citing works

Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies

Komatsubara, K. M., & Carvajal, R. D. (2017) · Current Oncology Reports · doi:10.1007/s11912-017-0606-5 · Cited by 88 · see citing works

Autoimmune Arthropathy and Uveitis as Complications of Programmed Death 1 Inhibitor Treatment

de Velasco, G., Bermas, B., & Choueiri, T. K. (2015) · Arthritis & Rheumatology · doi:10.1002/art.39406 · Cited by 84 · see citing works

Case of acute anterior uveitis and Vogt–Koyanagi–Harada syndrome‐like eruptions induced by nivolumab in a melanoma patient

Arai, T., Harada, K., Usui, Y., Irisawa, R., & Tsuboi, R. (2016) · The Journal of Dermatology · doi:10.1111/1346-8138.13612 · Cited by 84 · see citing works

BILATERAL DRUG (IPILIMUMAB)-INDUCED VITRITIS, CHOROIDITIS, AND SEROUS RETINAL DETACHMENTS SUGGESTIVE OF VOGT–KOYANAGI–HARADA SYNDROME

Wong, R., Lee, J. K., & Huang, J. J. (2012) · Retinal Cases & Brief Reports · doi:10.1097/icb.0b013e31824f7130 · Cited by 80 · see citing works

Cytogenetic Abnormalities in Uveal Melanoma Based on Tumor Features and Size in 1059 Patients

Shields, C. L., Say, E. A. T., Hasanreisoğlu, M., et al. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2016.12.026 · Cited by 79 · see citing works

Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O)

Kelderman, S., van der Kooij, M. K., van den Eertwegh, A. J. M., Soetekouw, P. M. M. B., Jansen, R. L. H., van den Brom, R. R. H., Hospers, G. A. P., Haanen, J. B. A. G., Kapiteijn, E., & Blank, C. U. (2013) · Acta Oncologica · doi:10.3109/0284186x.2013.786839 · Cited by 78 · see citing works

A Case of Bilateral Uveitis and Papillitis in a Patient Treated with Pembrolizumab

Samra, K. A., Valdes-Navarro, M., Lee, S., et al. (2015) · European Journal of Ophthalmology · doi:10.5301/ejo.5000724 · Cited by 78 · see citing works

Ipilimumab-Induced Hypophysitis and Uveitis in a Patient With Metastatic Melanoma and a History of Ipilimumab-Induced Skin Rash

Nallapaneni, N. N., Mourya, R., Bhatt, V. R., Malhotra, S., Ganti, A. K., & Tendulkar, K. K. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0105 · Cited by 74 · see citing works

Pembrolizumab-induced myasthenia gravis: A fatal case report

March, K. L., Samarin, M. J., Sodhi, A., & Owens, R. E. (2017) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155216687389 · Cited by 73 · see citing works

Vogt‐Koyanagi‐Harada disease‐like posterior uveitis in the course of nivolumab (anti‐PD‐1 antibody), interposed by vemurafenib (BRAF inhibitor), for metastatic cutaneous malignant melanoma

Matsuo, T., & Yamasaki, O. (2017) · Clinical Case Reports · doi:10.1002/ccr3.911 · Cited by 73 · see citing works

Ipilimumab-Associated Bilateral Optic Neuropathy

Yeh, O. L., & Francis, C. E. (2015) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000217 · Cited by 72 · see citing works

Acute visual loss after ipilimumab treatment for metastatic melanoma

Wilson, M. A., Guld, K., Galetta, S. L., Walsh, R. D., Kharlip, J., Tamhankar, M. A., McGettigan, S., Schuchter, L. M., & Fecher, L. A. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0170-9 · Cited by 71 · see citing works

PD-1 checkpoint inhibition: Toxicities and management

Hahn, A. W., Gill, D. M., Agarwal, N., & Maughan, B. L. (2017) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2017.08.005 · Cited by 67 · see citing works

Cyclosporine for Dry Eye Associated With Nivolumab

Nguyen, A. T., Elia, M., Materin, M. A., Sznol, M., & Chow, J. (2016) · Cornea · doi:10.1097/ico.0000000000000724 · Cited by 66 · see citing works

Bilateral Choroidopathy and Serous Retinal Detachments During Ipilimumab Treatment for Cutaneous Melanoma

Mantopoulos, D., Kendra, K. L., Letson, A. D., et al. (2015) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2015.1128 · Cited by 64 · see citing works

Immune Checkpoint Inhibitors for Treatment of Metastatic Melanoma of the Orbit and Ocular Adnexa

Ford, J., Thuro, B. A., Thakar, S. D., Hwu, W., Richani, K., & Esmaeli, B. (2016) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000000790 · Cited by 64 · see citing works

Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients

Nguyen, B., Kuo, J. C.-Y., Budiman, A., et al. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000310 · Cited by 62 · see citing works

Pembrolizumab for Recurrent Conjunctival Melanoma

Kini, A., Fu, R., Compton, C., et al. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.2279 · Cited by 62 · see citing works

Paraneoplastic Vitelliform Retinopathy: Clinicopathologic Correlation and Review of the Literature

Aronow, M. E., Adamus, G., Abu-Asab, M. S., et al. (2012) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2012.02.004 · Cited by 61 · see citing works

Chorioretinal Lesions in a Case of Melanoma-Associated Retinopathy Treated With Pembrolizumab

Roberts, P. K., Fishman, G. A., Joshi, K., et al. (2016) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2016.2944 · Cited by 61 · see citing works

Myasthenia gravis induced by nivolumab therapy in a patient with non–small‐cell lung cancer

Polat, P., & Donofrio, P. D. (2016) · Muscle & Nerve · doi:10.1002/mus.25163 · Cited by 58 · see citing works

PEMBROLIZUMAB ADMINISTRATION ASSOCIATED WITH POSTERIOR UVEITIS

Aaberg, M. T., & Aaberg, T. M. (2016) · Retinal Cases & Brief Reports · doi:10.1097/icb.0000000000000368 · Cited by 58 · see citing works

PD-1/PD-L1 Inhibitors for Immuno-oncology: From Antibodies to Small Molecules

Geng, Q., Jiao, P., Jin, P., et al. (2018) · Current Pharmaceutical Design · doi:10.2174/1381612823666171004120152 · Cited by 57 · see citing works

Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: Case report

Basilious, A., & Lloyd, J. C. (2016) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2015.09.008 · Cited by 56 · see citing works

Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma

Hahn, L., & Pepple, K. L. (2016) · Journal of Ophthalmic Inflammation and Infection · doi:10.1186/s12348-016-0082-3 · Cited by 52 · see citing works

Pembrolizumab-triggered Uveitis: An Additional Surrogate Marker for Responders in Melanoma Immunotherapy?

Diem, S., Keller, F., Rüesch, R., Maillard, S. A., Speiser, D. E., Dummer, R., Siano, M., Urner-Bloch, U., Goldinger, S. M., & Flatz, L. (2016) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000143 · Cited by 52 · see citing works

A Rare Case of Pembrolizumab‐Induced Uveitis in a Patient with Metastatic Melanoma

Hanna, K. S. (2016) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1839 · Cited by 52 · see citing works

Factors predictive of return to work after stroke in patients with mild−moderate disability in India

Bonner, B., Pillai, R. S., Sarma, P. S., Lipska, K. J., Pandian, J. D., & Sylaja, P. N. (2015) · European Journal of Neurology · doi:10.1111/ene.12887 · Cited by 51 · see citing works

The autoimmune diseases of the eyes

de Andrade, F. A., Fiorot, S. H. S., Benchimol, E. I., Provenzano, J., Martins, V. J., & Levy, R. A. (2015) · Autoimmunity Reviews · doi:10.1016/j.autrev.2015.12.001 · Cited by 51 · see citing works

Anti-PD1 treatment in metastatic uveal melanoma in the Netherlands

van der Kooij, M. K., Joosse, A., Speetjens, F. M., et al. (2016) · Acta Oncologica · doi:10.1080/0284186x.2016.1260773 · Cited by 51 · see citing works

Myasthenia Gravis After Nivolumab Therapy for Squamous Cell Carcinoma of the Bladder

Chang, E., Sabichi, A. L., & Sada, Y. H. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000161 · Cited by 51 · see citing works

Anti–Cytotoxic T-Cell Lymphocyte Antigen-4–Induced Regression of Spinal Cord Metastases in Association With Renal Failure, Atypical Pneumonia, Vision Loss, and Hearing Loss

Voskens, C., Cavallaro, A., Erdmann, M., Dippel, O., Kaempgen, E., Schuler, G., Schuler‐Thurner, B., & Heinzerling, L. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.41.4359 · Cited by 49 · see citing works

Intraocular Inflammation Associated with New Therapies for Cutaneous Melanoma – Case Series and Review

Fierz, F. C., Meier, F., Chaloupka, K., et al. (2016) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/s-0042-102668 · Cited by 47 · see citing works

Multifocal bilateral choroidal neovascularization in a patient on ipilimumab for metastatic melanoma

Modjtahedi, B. S., Maïbach, H. I., & Park, S. (2013) · Cutaneous and Ocular Toxicology · doi:10.3109/15569527.2013.781618 · Cited by 46 · see citing works

Immune checkpoint inhibitors: Navigating a new paradigm of treatment toxicities

Roberts, K. E., Culleton, V., Lwin, Z., O'Byrne, K. J., & Hughes, B. G. M. (2017) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12698 · Cited by 46 · see citing works

Benign form of myasthenia gravis after nivolumab treatment

Sciacca, G., Nicoletti, A. S. Q., Rampello, L., et al. (2016) · Muscle & Nerve · doi:10.1002/mus.25212 · Cited by 45 · see citing works

Bilateral Anterior Uveitis Associated with Nivolumab Therapy

Karlin, J. N., Gentzler, R. D., & Golen, J. R. (2016) · Ocular Immunology and Inflammation · doi:10.1080/09273948.2016.1215473 · Cited by 45 · see citing works

The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma

Moser, J. C., Pulido, J. S., Dronca, R. S., et al. (2014) · Melanoma Research · doi:10.1097/cmr.0000000000000125 · Cited by 43 · see citing works

Ipilimumab-Associated Retinopathy

Crews, J. D., Agarwal, A. K., Jack, L. S., Xu, D., Diana, V., & Nguyen, Q. D. (2015) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20150610-10 · Cited by 42 · see citing works

Corneal graft rejection in a patient treated with nivolumab for primary lung cancer

Fournis, S. L., Gohier, P., Urban, T., Jeanfaivre, T., & Hureaux, J. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.10.008 · Cited by 42 · see citing works

IMMUNE RETINOPATHY ASSOCIATED WITH NIVOLUMAB ADMINISTRATION FOR METASTATIC NON–SMALL CELL LUNG CANCER

Reddy, M., Chen, J. J., Kalevar, A., et al. (2017) · Retinal Cases & Brief Reports · doi:10.1097/icb.0000000000000675 · Cited by 41 · see citing works

Inflammatory Orbitopathy Associated With Ipilimumab

Sheldon, C. A., Kharlip, J., & Tamhankar, M. A. (2015) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000000509 · Cited by 38 · see citing works

A case of new‐onset antibody‐positive myasthenia gravis in a patient treated with pembrolizumab for melanoma

Alnahhas, I., & Wong, J. (2016) · Muscle & Nerve · doi:10.1002/mus.25496 · Cited by 38 · see citing works

Uveitis induced by programmed cell death protein 1 inhibitor therapy with nivolumab in metastatic melanoma patient

Kanno, H., Ishida, K., Yamada, W., et al. (2017) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2017.04.007 · Cited by 36 · see citing works

A major responder to ipilimumab and nivolumab in metastatic uveal melanoma with concomitant autoimmunity

Chan, P. Y., Hall, P. E., Hay, G. R., et al. (2017) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12607 · Cited by 36 · see citing works

Bilateral Uveitis and Keratitis Following Nivolumab Treatment for Metastatic Melanoma

Baughman, D. M., Lee, C. S., Snydsman, B. E., et al. (2017) · Medical Case Reports · doi:10.21767/2471-8041.100044 · Cited by 36 · see citing works

New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient

Miserocchi, E., Cimminiello, C., Mazzola, M., Russo, V. E. A., & Modorati, G. M. (2015) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2014.10.010 · Cited by 35 · see citing works

Anti‐PD‐1 antibodies in metastatic uveal melanoma: a treatment option?

Bender, C., Enk, A., Gutzmer, R., et al. (2017) · Cancer Medicine · doi:10.1002/cam4.887 · Cited by 35 · see citing works

A Case Report of Orbital Inflammatory Syndrome Secondary to Ipilimumab

Henderson, A. D., & Thomas, D. A. (2014) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000000081 · Cited by 34 · see citing works

A case of recurrent bilateral uveitis independently associated with dabrafenib and pembrolizumab therapy

Taylor, S. C., Hrisomalos, F. N., Linette, G. P., et al. (2016) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2016.04.004 · Cited by 33 · see citing works

A Case Report of Drug-Induced Myopathy Involving Extraocular Muscles after Combination Therapy with Tremelimumab and Durvalumab for Non-Small Cell Lung Cancer

Carrera, W. M., Baartman, B. J., & Kosmorsky, G. S. (2017) · Neuro-Ophthalmology · doi:10.1080/01658107.2017.1291686 · Cited by 30 · see citing works

Bilateral uveitis associated with nivolumab therapy for metastatic melanoma: a case report

Richardson, D. R., Ellis, B., Mehmi, I., et al. (2017) · International Journal of Ophthalmology · doi:10.18240/ijo.2017.07.28 · Cited by 30 · see citing works

Cutaneous Melanoma Metastatic to the Orbit

Greene, D. P., Shield, D. R., Shields, C. L., et al. (2014) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0000000000000075 · Cited by 28 · see citing works

Combination Ipilimumab and Nivolumab for Metastatic Melanoma Associated With Ciliochoroidal Effusion and Exudative Retinal Detachment

Tsui, E. Y. K., Madu, A., Belinsky, I., et al. (2017) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2017.4872 · Cited by 28 · see citing works

Bilateral anterior uveitis and unilateral facial palsy due to ipilimumab for metastatic melanoma in an individual with human leukocyte antigen DR4: A case report

Numata, S., Iwata, Y., Okumura, R., Arima, M., Kobayashi, T., Watanabe, S., Suzuki, K., Horiguchi, M., & Sugiura, K. (2017) · The Journal of Dermatology · doi:10.1111/1346-8138.13779 · Cited by 27 · see citing works

Myasthenia Gravis Induced by Nivolumab in Patients with Non-Small-Cell Lung Cancer: A Case Report and Literature Review

Hasegawa, Y., Kawai, S., Ota, T., Tsukuda, H., & Fukuoka, M. (2017) · Immunotherapy · doi:10.2217/imt-2017-0043 · Cited by 23 · see citing works

BILATERAL METASTATIC CUTANEOUS MELANOMA TO RETINA AND VITREOUS AFTER IPILIMUMAB TREATED WITH PARS PLANA VITRECTOMY AND RADIOTHERAPY

Kanavati, S., Ottensmeier, C. H. H., Foria, V., et al. (2016) · Retinal Cases & Brief Reports · doi:10.1097/icb.0000000000000477 · Cited by 21 · see citing works

Nonantibestrophin Anti-RPE Antibodies in Paraneoplastic Exudative Polymorphous Vitelliform Maculopathy

Dalvin, L. A., Johnson, A. A., Pulido, J. S., et al. (2015) · Translational Vision Science & Technology · doi:10.1167/tvst.4.3.2 · Cited by 19 · see citing works

In vivo Confocal Microscopy in Differentiating Ipilimumab-Induced Anterior Uveitis from Metastatic Uveal Melanoma

Kıratlı, H., Mocan, M. C., & Irkec, M. T. (2016) · Case Reports in Ophthalmology · doi:10.1159/000448730 · Cited by 18 · see citing works

Cancer Therapy with Checkpoint Inhibitors: Establishing a Role for Ophthalmology

Davis, M. E., & Francis, J. H. (2017) · Seminars in Oncology Nursing · doi:10.1016/j.soncn.2017.08.003 · Cited by 15 · see citing works

Re

Sohrab, M. A., Desai, R. U., Chambers, C. B., & Lissner, G. S. (2013) · Ophthalmic Plastic and Reconstructive Surgery · doi:10.1097/iop.0b013e3182895795 · Cited by 14 · see citing works

Disparity in PD-L1 expression between metastatic uveal and cutaneous melanoma.

Javed, A., Arguello, D., Johnston, C., Gatalica, Z., Orloff, M. M., Mastrangelo, M. J., & Sato, T. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9541 · Cited by 9 · see citing works

New Translational Research in the Medical Management of Orbital Melanoma

Glass, L. D., Sullivan, R. J., & Freitag, S. K. (2016) · Seminars in Ophthalmology · doi:10.3109/08820538.2015.1114849 · Cited by 5 · see citing works

Choroidal Metastases From Cutaneous Melanoma

Mercado, C. L., Toy, B. C., Kistler, H. B., et al. (2016) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/23258160-20160419-17 · Cited by 4 · see citing works

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Thompson, J. A., Schneider, B. J., Brahmer, J., Andrews, S., Armand, P., Bhatia, S., Budde, L. E., Costa, L., Davies, M., Dunnington, D., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0013 · Cited by 570 · see citing works

Ocular Adverse Events Associated with Mek Inhibitors

Méndez-Martínez, S., Calvo, P., Ruiz-Moreno, O., Pardiñas Barón, N., Leciñena Bueno, J., Gil Ruiz, M. D. R., & Pablo, L. (2019) · Retina · doi:10.1097/iae.0000000000002451 · Cited by 117 · see citing works

Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)

Peiffert, M., Cugnet-Anceau, C., Dalle, S., Chikh, K., Assaad, S., Disse, E., Raverot, G., Borson-Chazot, F., & Abeillon-du Payrat, J. (2021) · Cancers · doi:10.3390/cancers13081944 · Cited by 33 · see citing works

Single-cell transcriptomic analysis of retinal immune regulation and blood-retinal barrier function during experimental autoimmune uveitis

Quinn, J., Salman, A., Paluch, C., Jackson-Wood, M., McClements, M. E., Luo, J., Davis, S. J., Cornall, R. J., MacLaren, R. E., Dendrou, C. A., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-68401-y · Cited by 32 · see citing works

Combined effect of ipilimumab and nivolumab improves oncology endpoints in metastatic melanoma patients

Wahid, M., Mandal, R. K., Jawed, A., Alsulimani, A., Hashem, A. M., Harakeh, S., Hussain, A., Fagoonee, S., Pellicano, R., & Haque, S. (2023) · Biotechnology and Genetic Engineering Reviews · doi:10.1080/02648725.2022.2147683

Utility Values Across Lines of Therapy in Immuno-Oncology Treatments: An Example from Advanced Melanoma

Tilden, D., Sierakowski, W., Cottrell, S., et al. (2017) · Value in Health · doi:10.1016/j.jval.2017.08.289

Prolonged Benefit from Ipilimumab Correlates with Improved Outcomes from Subsequent Pembrolizumab

Shreders, A. J., Joseph, R. W., Peng, C., Ye, F., Zhao, S., Puzanov, I. J., Sosman, J. A., & Johnson, D. B. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0281 · Cited by 21 · see citing works

The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysisPreprint

Gu, L., Li, S., Du, N., Yao, Q., Fu, X., Lou, Y., Wang, M., Mao, F., Mao, D., Khadaroo, P. A., et al. (2020) · doi:10.21203/rs.3.rs-17064/v1

Japanese real‐world study of sequential nivolumab and ipilimumab treament in melanoma

Tsutsumida, A., Fukushima, S., Yokota, K., et al. (2019) · The Journal of Dermatology · doi:10.1111/1346-8138.15073 · Cited by 17 · see citing works